Emergent BioSolutions (EBS) Gross Profit (2011 - 2026)
Emergent BioSolutions' Gross Profit came in at $29.2 million for Q3 2026, down 79.9% from $145.2 million a year earlier and down 78.7% from the prior quarter.
Powered by 
Analysis
Emergent BioSolutions (EBS) Gross Profit (2011 - 2026) Analysis & Trends
Over the trailing twelve months to Sep 30, 2026, Emergent BioSolutions reported Gross Profit of $314.3 million, down 26.8% year-over-year; for FY2025, it came in at $416.7 million, up 15.0% from FY2024.
- Gross Profit carries a five-year compound annual growth rate of -16.7% (FY2020 to FY2025).
- Going back by year, Gross Profit was $362.3 million in FY2024 (+5.4%), $343.9 million in FY2023 (-19.0%), $424.4 million in FY2022 (-58.6%) and $1.03 billion in FY2021 (-1.4%).
- The Q3 2026 figure represents the lowest quarterly Gross Profit since Q2 2024.
- Year-over-year, Gross Profit increased in 1 of the last seven quarters, with an average decline of 13.4%.
- The fastest year-over-year change in Gross Profit over five years came in Q2 2023 (growth of 102.3%), and the weakest in Q1 2023 (a decline of 92.3%).
- Business Quant data shows EBS's Gross Profit at $137.2 million (Q2 2026), $84.1 million (Q1 2026) and $63.8 million (Q4 2025) in the three quarters before Q3 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn |
| 10 | Emergent BioSolutions | 310.37 Mn | -370.73 Mn | 29.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 29.20 Mn |
| Jun 30, 2026 | 137.20 Mn |
| Mar 31, 2026 | 84.10 Mn |
| Dec 31, 2025 | 63.80 Mn |
| Sep 30, 2025 | 145.20 Mn |
| Jun 30, 2025 | 74.00 Mn |
| Mar 31, 2025 | 133.70 Mn |
| Dec 31, 2024 | 76.70 Mn |
| Sep 30, 2024 | 171.20 Mn |
| Jun 30, 2024 | -41.40 Mn |
| Mar 31, 2024 | 155.80 Mn |
| Dec 31, 2023 | 91.50 Mn |
| Sep 30, 2023 | 93.70 Mn |
| Jun 30, 2023 | 147.30 Mn |
| Mar 31, 2023 | 11.40 Mn |
| Dec 31, 2022 | 109.70 Mn |
| Sep 30, 2022 | 92.70 Mn |
| Jun 30, 2022 | 72.80 Mn |
| Mar 31, 2022 | 148.90 Mn |
| Dec 31, 2021 | 529.40 Mn |
API Access
Emergent BioSolutions Gross Profit API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=gross-profit&ticker=EBS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "gross-profit", "ticker": "EBS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=gross-profit&ticker=EBS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();